The global dental regeneration market size is expected to reach USD 7.8 billion by 2030, expanding at 6.1% CAGR from 2023 to 2030, according to a new report by Grand View Research, Inc. The key factors driving the growth of the market are the increasing incidence of tooth loss and the growing geriatric population.
For instance, according to WHO, in 2022, 3.5 billion people were affected by oral diseases. It is estimated globally that 514 million children are affected by caries of primary teeth and 2.0 billion people are impacted by dental caries of permanent teeth. However, the loss of teeth is typically the result of a lifelong history of oral disease, primarily advanced dental caries, and severe periodontal disease.
Dental regeneration is a therapeutic regenerative process that uses stem cell biology and tissue engineering. The dental regeneration procedure includes restoring the structural defects of teeth conditions & the collection of stem cells. It is a novel invention in next-generation therapies. Developing new therapies for tooth generation has been a key focus of research in the field. In addition to regenerative procedures, this new technology can also improve the aesthetics of the mouth.
The COVID-19 pandemic had a negative effect on the global market for dental regeneration as fewer surgeries were conducted during the pandemic. Due to the virus's transmission route, which typically involves exposure to aerosols and droplets, dentists were much more prone to get an infection while treating patients. Hence, the dental sector was significantly impacted by the coronavirus. Consequently, COVID-19 led to fewer dental visits, particularly during lockdown. For instance, according to a research study published in the International Journal of Environmental Research and Public Health, interest in dental services decreased to 37% as compared to the year before the pandemic.
Request a free sample copy or view report summary: Dental Regeneration Market Report
The hard tissue regeneration segment dominated the market in 2025 and is expected to grow over the forecast period, driven by strong demand for bone grafts and related biomaterials used in implant site development, periodontal defect treatment, and alveolar ridge augmentation.
Based on end-users, dental clinics are anticipated to register the fastest CAGR growth during the forecast period
The geriatric segment dominated the dental regeneration industry in 2025, driven by the higher prevalence of tooth loss, periodontal disease, and alveolar bone resorption among older adults.
North America region accounted for the largest share of 39.63% in 2025. The growing prevalence of dental diseases and rising developments in dental regenerative procedures are the key factors driving the growth of the market in the region
Grand View Research has segmented the global dental regeneration market based on type, age group, end user, and region:
Dental Regeneration Type Outlook (Revenue, USD Million, 2021 - 2033)
Hard Tissue
Dentin
Cementum
Enamel
Soft Tissue
Gum
Pulp
Dental Regeneration Age Group Outlook (Revenue, USD Million, 2021 - 2033)
Pediatric
Adult
Geriatric
Dental Regeneration End User Outlook (Revenue, USD Million; 2021 - 2033)
Hospitals
Dental Clinics
Others
Dental Regeneration Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Sweden
Denmark
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Dental Regeneration Market
Bioteck S.p.A.
Dentsply Sirona
Maxigen Biotech Inc. (TCI Co., Ltd.)
Institut Straumann AG
Nobel Biocare Services AG (Envista)
Geistlich Holding
ZimVie Inc.
NovaBone (Halma)
Osteogenics Biomedical (Envista)
Regenity
Medtronic
BioHorizons
REGEDENT AG
IDL Dental Technologies LTD
EUCARE PHARMACEUTICALS (P) LTD
Curasan, Inc.
TBR Dental
DentiumUSA
Tecnoss Dental Srl (Tecnoss s.r.l.)
Unicare Biomedical, Inc.
Neoss
Advanced Medical Solutions Group plc
B&B Dental Implant Company
Botiss
Septodont Holding
Implant Direct Corporation (Envista)
META BIOMED CO,. LTD
SigmaGraft Biomaterials
"The quality of research they have done for us has been excellent..."